Feasibility, yield, and cost of active tuberculosis case finding linked to a mobile HIV service in Cape Town, South Africa: a cross-sectional study by Kranzer, Katharina et al.
Feasibility, Yield, and Cost of Active Tuberculosis Case
Finding Linked to a Mobile HIV Service in Cape Town,
South Africa: A Cross-sectional Study
Katharina Kranzer1,2*, Stephen D. Lawn1,2, Gesine Meyer-Rath3,4,5, Anna Vassall3,6, Eudoxia Raditlhalo2,
Darshini Govindasamy2, Nienke van Schaik2, Robin Wood2, Linda-Gail Bekker2
1 Department of Clinical Research, Faculty of Infectious and Tropical Diseases, London School of Hygiene and Tropical Medicine, London, United Kingdom, 2 The
Desmond Tutu HIV Centre, Institute for Infectious Disease and Molecular Medicine, Faculty of Health Science, University of Cape Town, South Africa, 3 Department of
Global Health and Development, London School of Hygiene and Tropical Medicine, London, United Kingdom, 4 Health Economics and Epidemiology Research Office
(HE2RO), Department of Medicine, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa, 5 Center for Global Health and Development,
Boston University, Boston, United States of America, 6 Department of Development Policy and Practice, Royal Tropical Institute, Amsterdam, The Netherlands
Abstract
Background: The World Health Organization is currently developing guidelines on screening for tuberculosis disease to
inform national screening strategies. This process is complicated by significant gaps in knowledge regarding mass
screening. This study aimed to assess feasibility, uptake, yield, treatment outcomes, and costs of adding an active
tuberculosis case-finding program to an existing mobile HIV testing service.
Methods and Findings: The study was conducted at a mobile HIV testing service operating in deprived communities in
Cape Town, South Africa. All HIV-negative individuals with symptoms suggestive of tuberculosis, and all HIV-positive
individuals regardless of symptoms were eligible for participation and referred for sputum induction. Samples were
examined by microscopy and culture. Active tuberculosis case finding was conducted on 181 days at 58 different sites. Of
the 6,309 adults who accessed the mobile clinic, 1,385 were eligible and 1,130 (81.6%) were enrolled. The prevalence of
smear-positive tuberculosis was 2.2% (95% CI 1.1–4.0), 3.3% (95% CI 1.4–6.4), and 0.4% (95% CI 1.4 015–6.4) in HIV-negative
individuals, individuals newly diagnosed with HIV, and known HIV, respectively. The corresponding prevalence of culture-
positive tuberculosis was 5.3% (95% CI 3.5–7.7), 7.4% (95% CI 4.5–11.5), 4.3% (95% CI 2.3–7.4), respectively. Of the 56 new
tuberculosis cases detected, 42 started tuberculosis treatment and 34 (81.0%) completed treatment. The cost of the
intervention was US$1,117 per tuberculosis case detected and US$2,458 per tuberculosis case cured. The generalisability of
the study is limited to similar settings with comparable levels of deprivation and TB and HIV prevalence.
Conclusions: Mobile active tuberculosis case finding in deprived populations with a high burden of HIV and tuberculosis is
feasible, has a high uptake, yield, and treatment success. Further work is now required to examine cost-effectiveness and
affordability and whether and how the same results may be achieved at scale.
Please see later in the article for the Editors’ Summary.
Citation: Kranzer K, Lawn SD, Meyer-Rath G, Vassall A, Raditlhalo E, et al. (2012) Feasibility, Yield, and Cost of Active Tuberculosis Case Finding Linked to a Mobile
HIV Service in Cape Town, South Africa: A Cross-sectional Study. PLoS Med 9(8): e1001281. doi:10.1371/journal.pmed.1001281
Academic Editor: Madhukar Pai, McGill University, Canada
Received January 31, 2012; Accepted June 27, 2012; Published August 7, 2012
Copyright:  2012 Kranzer et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: The study was funded by the Wellcome Trust. KK and SDL had support from the Wellcome Trust, RW had support from IEDEA (5U01AI069924-02,
CEPAC (5 R01 AI058736-02), USAID Right to Care (CA 674 A 00 08 0000 700), CIPRA (IU19AI53217-07), LGB had support from NIH CIPRA (1U19AI053217). The
mobile clinic used in this study was funded by the following sources: USAID and Agence Francaise de Developpmen No funding bodies had any role in study
design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
Abbreviations: ART, antiretroviral therapy; DALY, disability-adjusted life-year; IQR, interquartile range; TB, tuberculosis; WHO, World Health Organization
* E-mail: katharina.kranzer@lshtm.ac.uk
PLoS Medicine | www.plosmedicine.org 1 August 2012 | Volume 9 | Issue 8 | e1001281
.       
Introduction
Active tuberculosis (TB) case finding in HIV-infected individ-
uals has been recommended by the World Health Organization
(WHO) as part of the ‘‘Three I’s’’ policy initiative [1,2]. Screening
of household contacts of infectious TB cases has been recom-
mended [3–5], but population-wide mass screening has been
widely discouraged because of high cost and poor sustainability
[6–8]. However, a recent study from Zimbabwe reported a decline
of TB prevalence from 6.5 to 3.7 per 1,000 adults associated with
community-level active TB case finding [6], leading to renewed
interest in population-wide interventions.
Active TB case finding aims to reduce barriers for early TB case
detection, including delays in presentation to health facilities,
identification of the person as a TB suspect, and initiation of
appropriate investigations. The ultimate goal of active TB case
finding is to reduce TB transmission in the community through
improved case detection and reduction in diagnostic delays [8].
The yield of active TB case finding defines the number of
individuals who need to be screened to identify each additional
new case. This yield is context specific, depending on TB and HIV
prevalence, TB control services, and specificity and sensitivity of
the screening tool used [9]. Other important parameters framing
decisions on implementing active TB case finding include the
feasibility and cost of screening, laboratory capacity, diagnostic
tests available, and treatment outcomes in newly detected cases.
The WHO is currently developing guidelines on screening for
TB disease to inform national TB screening strategies on the basis
of the local epidemiological, demographic, and health system
situation [7]. However, the development of these guidelines is
complicated by significant gaps in knowledge regarding mass
screening strategies in high TB and HIV prevalence settings. In
particular, the screening strategy, optimal choice of diagnostic test,
the cost of active TB case finding, and the treatment outcomes of
actively detected cases remain unclear.
We report the results of a study investigating the feasibility,
uptake, treatment outcomes, and cost of adding an active TB case-
finding program linked to an existing mobile HIV testing service in
Cape Town, South Africa.
Methods
Setting
This study was conducted at a mobile HIV testing service over
19 mo from May 2009 to February 2011. The service operated in
underserviced peri-urban areas in greater Cape Town, South
Africa [10]. This nurse-run and counsellor-supported mobile unit
provided free HIV counselling and testing in combination with
free screening for other chronic conditions (hypertension, diabetes,
and obesity) and TB. Rapid HIV testing was performed according
to the guidelines of the Provincial Government of the Western
Cape [11]. The mobile unit was parked at township shopping
centres, taxi ranks, stations, and the road side. The service was not
formally advertised. However, the mobile van was painted in
vibrant colours that therefore attracted a lot of attention. Most
locations were served at least on a 3-monthly basis to allow
individuals repeat testing.
Mobile Clinic Procedures
All individuals accessing the mobile clinic were registered using
a biometric fingerprint system, with no names or other personal
identifiers collected in the registration process (Figure 1). They
were then seen by a nurse for rapid HIV testing and chronic
disease screening, including TB symptom screening, followed by a
one-on-one counselling session. All individuals with conditions
needing follow-up such as newly diagnosed hypertension, diabetes,
HIV, or symptoms suggestive of TB (TB suspects) received a referral
letter to take to their nearest clinic for further evaluation. Symptoms
suggestive of TB were defined as cough for more than 2 wk,
unintentional weight loss, haemoptysis, fever, and night sweats.
Study Procedures
Screening. All HIV-negative adults with symptoms sugges-
tive of TB and all adults with HIV infection or diabetes regardless
of symptoms were eligible for the study. The lay counsellor
collected detailed contact information from these individuals and
referred them to the study nurse for participation in the study
(Figure 1). A questionnaire was administered to all consenting
individuals. They were asked to provide one sputum sample and
were encouraged to do so by sputum induction, but could choose
to provide a spot sample. Sputum samples were refrigerated
overnight and sent to the laboratory the following day. The
samples underwent fluorescence microscopy and liquid culture.
Sputum induction. Individuals were asked to rinse their
mouth with water before the procedure. Sputum induction was
performed outdoors in an open-roofed tent using 1.5–2-ml sterile
3% hypertonic saline solution and an ultrasonic Flo-Eolo nebuliser
(CA-Mi) powered by a generator. Individuals breathed through
the nebuliser mouthpiece until a satisfactory sample was produced.
Laboratory procedure. Sputum samples were analysed by
accredited public-sector laboratories. Following decontamination
with N-acetyl-L-cysteine sodium hydroxide, centrifuged sputum
deposits were examined for acid-fast bacilli using auramine-O-
fluorescent stain and cultured using mycobacterial growth
indicator tubes (MGIT, Becton-Dickinson). Bacillary density was
graded as scanty, 1+, 2+, and 3+, and all such smears were defined
as ‘‘smear-positive.’’ The time to automated culture growth
detection was recorded. Culture isolates positive for acid-fast
bacilli were identified as Mycobacterium tuberculosis or as Mycobac-
terium other than tuberculosis (MOTT) complex and assessed for
genotypic resistance using the MTBDRplus assay (Hain Life-
Figure 1. Procedures and patient flow in the mobile clinic. The
number indicate the squence of procedure each patient had to go
through.
doi:10.1371/journal.pmed.1001281.g001
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sciences). Isolates also underwent phenotypic resistance testing for
rifampicin and isoniazid by automated liquid MGIT culture.
Definitions. Symptom screen positive was defined as any of
the following: cough .2 wk, weight loss, fever, night sweats, or
haemoptysis. Patients with M. tuberculosis cultured from the sputum
sample were defined as cases of TB. TB treatment outcomes were
defined as cured, treatment completed, died, defaulted, and
treatment interruption.
Follow-up. TB results were received from the laboratory on a
daily basis by post and email. The laboratory contacted the research
nurse by phone with smear-positive results and by email with
culture-positive results, who then contacted individuals to inform
them of their positive result and refer them to a TB clinic of their
choice. If necessary, more than one attempt was made to contact
individuals either by phone, home visit, or letter. The patient was
given a referral letter or the referral letter was sent and faxed to the
nearest TB clinic. Clinics were contacted by the research nurse to
ascertain each patient’s date of TB treatment initiation, TB register
number, treatment outcomes, and date of outcome. The research
nurse performed clinic visits to validate the information and check
the TB register. Individuals who did not attend the clinic were
contacted again to encourage linkage to care.
Cost Analysis
An incremental cost analysis investigating the cost of adding TB
screening using sputum induction to the existing mobile HIV
testing service was performed adopting a health service provider
perspective. Financial costs included the costs of human resources
(clinical nurse practitioner, programme manager, counsellor),
equipment, consumables, transport, laboratory tests, and office
rent and overhead. Costs were divided into capital and recurrent
costs [12], and capital costs were annualized and discounted at 6%
per year [13]. Cost data from previous years were adjusted for
inflation to 2011 constant costs [14] and converted to US$
(US$1.00 = ZAR 7.40) [15]. Some of the resources such as staff
and space were jointly used with other services and were allocated
proportionally. In order to analyse what staff time had been spent
exclusively on TB screening activities, time-motion studies of all
staff involved were conducted over 1 wk in August 2010 and 2 wk
in January 2011, with a total of 13 complete screening days being
observed. The two time periods were chosen because of seasonal
variations in attendance rates and working conditions. Details of
costs, proportional allocation, and time spent on screening are
presented in Tables S1 and S2. Additionally, the research nurse
kept a log file to estimate staff time spent on follow-up of
individuals with positive smears and/or cultures. The additional
diagnostic costs outside the mobile clinic were included. All
individuals were asked about additional diagnostic tests such as
chest X-rays, smears, and cultures performed in the primary
health care clinic, which were then taken into account. Cost of
first-line TB treatment was obtained from the literature [16,17].
For patients who died or defaulted treatment, costs were allocated
proportionately on the basis of their time spent on treatment.
Sensitivity analyses were conducted for different levels of staff
salaries and 0% and 3% discount rates for capital costs, assuming
that the outcomes would remain the same. The study was
conducted by a clinical nurse practitioner (research nurse) and a
doctor (program manager). A clinical nurse practitioner is a
registered nurse with additional training to enable her to do a
physical examination and prescribe medication. The sensitivity
analysis was conducted substituting the clinical nurse practitioner
by a staff nurse or a lay counsellor. A staff nurse is a nurse with 2 y
training. A lay counsellor undergoes 6 wk of disease-specific
training.
Measure of effectiveness. Effectiveness was measured as
the prevalence of smear- and/or culture-positive disease detected,
and the proportion of individuals with TB disease with a positive
treatment outcome (cured or treatment completed).
Statistical Analysis and Sample Size
Sample size calculations were based on precision. Pilot data
showed that HIV-infected clients accessing the mobile service were
less immuno-deficient than clients accessing stationary services
[10]. Therefore a lower yield of TB screening was assumed in
these individuals compared to the median yield of 8.5% in
stationary services [9]. Sample size calculation assumed an overall
yield of 2.5% (precision of 61%) and 5% (precision of 61.5%).
Estimated sample sizes were 937 and 811. 1,200 individuals were
predicted to be eligible over a 20-mo recruitment period (TB
screening: 2 d per week, seven eligible individuals per day), and
20% of them were assumed to not undergo screening.
All analyses were carried out using Stata version 11.0 (Stata
Corp. LP). Proportions were calculated for categorical variables,
and medians and interquartile ranges (IQR) for continuous
variables. The mean cost per examined sputum and TB case
identified was calculated by summing the cost of all resources used
for screening and dividing them by the number of sputum samples
and TB cases diagnosed. The mean incremental cost per TB case
with positive treatment outcome was calculated by summing the
cost of all resources including treatment costs and dividing them
by the number of TB cases with positive outcomes.
Results
Operational Data
TB screening was performed on 181 d over a period of 19 mo
at 58 different sites. The majority of sites were in deprived areas,
near townships and squatter camps (Figure 2). A total of 6,394
adults accessed the services of the mobile clinic: 85 were not tested
for HIV, 5,551 tested HIV negative, 370 were newly diagnosed
with HIV, and 388 were known HIV positive. Overall HIV
prevalence in individuals tested was 11.9%. The median number
of adults tested for HIV per day was 34 (IQR 27–41). The median
number of individuals screened for TB was 6 (IQR 3–8), with a
maximum number of 23 individuals per screening day.
Uptake of TB Screening
A total of 1,385 individuals (21.7% of all adults accessing the
service) were eligible for TB screening through sputum induction:
627 were HIV negative, 370 were newly diagnosed HIV positive,
and 388 were known HIV positive (Figure 3). 1,130 (81.6%) of all
eligible individuals underwent screening. Individuals who were not
screened were younger, more likely to be HIV positive, and had a
higher body mass index (BMI) compared to individuals who
underwent TB screening.
Of the 255 individuals who failed to undergo screening, 164
individuals did not want to wait or left without seeing the TB
nurse, and 91 individuals were missed because the nurses or
counsellors did not refer them for screening.
Of the eligible individuals 118 individuals were unable to
produce a sputum sample, and 164 individuals had a contam-
inated sputum result. Overall, 60.9% of all eligible individuals had
an interpretable sputum result (Figure 3).
Baseline Characteristics
The median age of patients undergoing screening was 35.9 y, and
35.9% were men (Table 1). The majority of individuals lived in
informal settlements or squatter camps (63.1%) and had less than
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12 y of school education (78.0%), the minimum requirement to
enter tertiary education. Financial insecurity was high with 22.7%
of individuals reporting no regular income. Among individuals with
regular income, only 35.3% were in employment or regular work.
The median income was ZAR 1,000 (equivalent to US$135) per
month. The national poverty line in 2008 was ZAR 515 per month
and the average minimum wage for 2011 ZAR 1,500 per month.
Median BMI was 24.4 (IQR 21.4–29.4). A quarter of individuals
had a history of previous TB. The median CD4 count was 434 cells/
ml (IQR 316–617) in newly diagnosed and 403 cells/ml (IQR 288–
570) in known HIV-infected individuals. 40% of the known HIV-
infected individuals were on antiretroviral therapy (ART) at the time
of screening with a median time on ART of 3.1 y (IQR 1.1–6.5).
The most prevalent TB symptom among HIV negative TB
suspects was cough (84.3%). A total of 160 (55.6%) of the newly
diagnosed and 162 (52.6%) of the known HIV-infected individuals
screened positive for TB symptoms. Only 20.7% (n = 170) of all
individuals reporting symptoms had previously sought health care
for their current symptoms. Of those who had sought health care,
61.8% had undergone sputum investigations and 31.8% had had
chest radiography.
Yield of TB Screening
Among all HIV-negative individuals (n = 5,551) or individuals
with unknown HIV status (n = 85) who accessed the mobile service
and were potentially eligible for TB screening, including those who
were unable to provide a sputum sample, prevalence was 0.2%
(95% CI 0.1–0.4) for smear-positive TB and 0.5% (95% CI 0.3–
0.7) for culture-positive TB. Among individuals newly diagnosed
with HIV, TB prevalence was 2.2% (95% CI 0.9–4.2) for smear-
positive and 4.9% (95% CI 2.9–7.6) for culture-positive disease.
Prevalence was 0.3% (95% CI 0–1.4) for smear-positive and 3.1%
(95% CI 1.6–5.3) for culture-positive TB in individuals with
known HIV infection.
The prevalence of smear-positive disease among individuals
providing a sputum sample was 2.0% (95% CI 1.2–3.0) (Table 2).
The prevalence of smear-positive TB was 2.2% (95% CI 1.1–4.0),
3.3% (95% CI 1.4–6.4), and 0.4% (95% CI 0–2.0) in HIV-
negative TB suspects, those with newly diagnosed HIV infection,
and those with known HIV infection, respectively. Prevalence of
culture-positive TB was 5.5% (95% CI 4.2–7.1) overall. Median
time to culture-positivity was 13.5 d (IQR 8–22). All isolates were
sensitive to rifampicin and isoniazid.
TB prevalence was highest in HIV-infected patients with CD4
counts #200 cells/ml (18.6%; 95% CI 9.7–30.9), followed by
patients with missing CD4 counts (7.7%; 95% CI 0.9–25.1). TB
prevalence was 5.3% (95% CI 2.0–11.1), 4.3% (95% CI 1.6–9.1),
and 2.8% (95% CI 0.9–6.3) in HIV-infected patients with CD4
counts of 201–350, 351–500, and .500 cells/ml, respectively.
Contact Rates, Treatment Initiation, and Treatment
Outcomes
A total of 56 individuals were diagnosed with TB. The baseline
characteristics and symptoms are described in Table S3. Successful
follow-up contact was made with 50 individuals (89.3%, 95% CI
78.1–96.0) (Table 3). Contact success was higher in those with
smear-positive disease (95.0%, 95% CI 75.1–99.9) compared to
those with smear-negative/culture-positive disease (86.1%, 95%
CI 70.5–95.3). The median time to successful contact from time of
positive result was 4 d (IQR 1–10) and was shorter for individuals
with smear-positive TB (1 d, IQR 0–2). Successful contacting of
patients with smear-positive disease rarely required more than one
attempt, whereas contact of smear-negative cases involved one to
two phone calls and often a home visit.
Of the 50 individuals contacted, a total of 42 (84.0%) were
confirmed to have started TB treatment. The median time
between screening and treatment initiation was 27 d (IQR 7–54)
overall, 6.5 d (IQR 4.5–8) for smear-positive and 45 d (IQR 32–
Figure 2. Map of Cape Town indicating the main areas in which
the mobile services operated. (1) Athlone: testing at a shopping
mall/market, the roadside, a social housing project; (2) Cape Town city
bowel: testing at a college, service for homeless, service for commercial
sex workers, two companies, two road sides; (3) Delft: testing at two
squatter camps, two clinics, two social housing projects, the road side;
(4) Durbanville: testing at two taxi ranks; (5) Grassy Park: testing at the
road side; (6) Guguletu: testing at two shopping malls/markets, a clinic;
(7) Hout Bay: testing at a school, in a township, at the harbour; (8)
Khayelitsha: testing at a shopping centre/market, a school, in the
township, at the station; (9) Macassar: testing at the road side; (10)
Kraaifontain: testing at a clinic; (11) Langa: testing at a shopping mall/
market, the road side; (12) Masiphumelele: testing in the township, at a
shopping mall; (13) Milnerton: testing at a company; (14) Mitchells Plain:
testing at the road side, a social housing project; (15) Belhar: testing at a
squatter camp; (16) Nyanga: testing at a taxi rank, at a shopping centre;
(17) Ocean View: testing at a clinic, in the township; (18) Parkwood:
testing at two road sides; (19) Phillippi: testing at two farms, three road
sides; (20) Retreat: testing at a clinic; (21) Wynberg: testing at the road
side; (22) Claremont: testing at the road side; (23) Grabouw: testing in
the township, at the clinic, at the road side.
doi:10.1371/journal.pmed.1001281.g002
Figure 3. Flowchart of individuals participating in the study.
doi:10.1371/journal.pmed.1001281.g003
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Table 1. Socio-demographic and clinical characteristics and health-seeking behaviour among those undergoing screening.
Variables Total (n = 1,130) HIV2 (n = 534)
Newly Diagnosed
HIV+ (n = 288)
Known HIV
+ (n = 239)
Socio-demographic (n = 1,130)
Median (IQR) age (y) 35.9 (27.9–45.7) 40.2 (29.2–50.0) 33.4 (26.4–40.9) 33.5 (28.2–40.8)
n (%) male gender 406 (35.9%) 261 (48.9%) 96 (33.3%) 49 (15.9%)
Smokinga
n (%) never 656 (58.2%) 224 (42.0%) 197 (68.6%) 235 (76.6%)
n (%) stopped 13 (1.2%) 8 (1.5%) 2 (0.7%) 3 (1.0%)
n (%) currently 458 (40.6%) 301 (56.5%) 88 (30.7%) 69 (22.5%)
Alcohol consumptionb
n (%) never 644 (57.2%) 280 (52.7%0 160 (55.6%) 204 (66.5%)
n (%) once per week 229 (20.3%) 98 (18.5%) 67 (23.3%) 64 (20.9%)
n (%) 2–3 times per week 190 (16.9%) 108 (20.3%) 52 (18.1%) 30 (9.8%)
n (%) every day 63 (5.6%) 45 (8.5%) 9 (3.1%) 9 (2.9%)
Current relationshipc
n (%) single 677 (60.0%) 296 (55.4%) 184 (63.9%) 197 (64.4%)
n (%) partner 377 (33.4%) 199 (37.3%) 85 (29.5%) 93 (30.4%)
n (%) divorced 22 (2.0%) 15 (2.8%) 4 (1.4%) 3 (1.0%)
n (%) widowed 52 (4.6%) 24 (4.5%) 15 (5.25) 13 (4.3%)
n (%) regular income 985 (87.3%) 472 (88.2%) 239 (83.0%) 275 (89.6%)
Source of income
n (%) government grants 259 (26.5%) 121 (26.0%) 40 (16.7%) 98 (35.8%)
n (%) casual work 375 (38.3%) 184 (39.5%) 96 (40.2%) 95 (34.7%)
n (%) regular work 345 (35.3%) 161 (34.6%) 103 (43.1%) 81 (29.6%)
Median (IQR) income per month (ZAR) 1,000 (400–1,200) 1,000 (400–1,200) 870 (280–1,200) 960 (400–1,120)
Level of schooling
n (%) none 45 (4.00) 29 (5.4%) 6 (2.1%) 10 (3.3%)
n (%) less than 8 y 369 (32.7%) 218 (41.0%) 84 (29.2%) 67 (21.8%)
n (%) 8–11 y 465 (41.3%) 192 (36.1%) 122 (42.4%) 151 (49.2%)
n (%) finished high school 159 (14.1%) 49 (9.2%) 52 (18.1%) 58 (18.9%)
n (%) tertiary education 89 (7.9%) 44 (8.3%) 24 (8.3%) 21 (6.8%)
n (%) participant ever having been imprisoned 159 (14.1%) 92 (17.2%) 39 (13.5%) 28 (9.1%)
n (%) participant living in informal settlementd 712 (63.1%) 304 (57.0%) 207 (71.9%) 201 (65.3%)
Clinical (n = 1,130)
n (%) diabetes 48 (4.3%) 36 (6.8%) 3 (1.1%) 9 (2.9%)
Median (IQR) BMI 24.4 (21.4–29.4) 22.7 (20.2–27.4) 25.1 (22.2–30.1) 26.5 (23.3–30.9)
Median (IQR) current CD4 count (cells/ml)e NA NA 434 (316–617) 403 (288–570)
n (%) currently on ARTf NA NA NA 120 (39.0%)
Median (IQR) time on ART (y) NA NA NA 3.1 (1.1–6.5)
Previous TB episode
n (%) none 845 (74.8%) 402 (75.3%) 247 (85.8%) 196 (63.6%)
n (%) one 247 (21.9%) 115 (21.5%) 37 (12.9%) 95 (30.8%)
n (%) more than one 38 (3.4%) 17 (3.2%) 4 (1.4%) 17 (5.5%)
n (%) TB within the last 2 y 133 (11.8%) 60 (11.2%) 15 (5.2%) 58 (18.8%)
n (%) TB household contact 240 (21.2%) 121 (22.7%) 63 (21.9%) 56 (18.2%)
Symptoms
n (%) cough 707 (62.6%) 450 (84.3%) 124 (43.1%) 133 (43.2%)
n (%) haemoptysis 126 (11.2%) 94 (17.6%) 14 (4.9%) 18 (5.8%)
n (%) fever 119 (10.5%) 75 (14.0%) 21 (7.3%) 23 (7.47%)
n (%) night sweats 628 (55.6%) 395 (74.0%) 115 (39.9%) 118 (38.3%)
n (%) weight loss 458 (40.5%) 284 (53.2%) 78 (27.1%) 96 (31.2%)
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57) for smear-negative/culture-positive cases. The median time
between successful contact and treatment initiation was 1 d (IQR
0–8). Most individuals (30/42) who were initiated on treatment
were initiated within 7 d following a successful contact. Thus the
majority of individuals only needed one successful contact to link
them to care.
The overall treatment success rate was 81.0% (n = 34/42) (95%
CI 65.9–91.4). Two individuals died while on treatment, five
defaulted, and one interrupted treatment, but restarted treatment
3 mo later.
Of the 42 individuals who had initiated treatment, seven had
started before a successful contact could be made (Figure 4). In
these cases, the initiation of treatment was not triggered by the
positive sputum result. These seven individuals had presented with
their referral letter to a primary care clinic and were started on TB
treatment on the basis of clinical presentation and investigations
performed at the clinic.
Costs
The incremental cost of actively screening 1,130 individuals for
TB including treatment costs was US$83,559. US$22,367 (26.8%)
were spent on laboratory tests, US$37,427 (44.8%) on staff
salaries, and US$17,652 (21.1%) on TB treatment, with the
remaining US$6,108 (7.3%) spent on transport, office rent and
utilities, communication, and supplies (Table S1). The costs were
US$1,117 per TB case detected and US$2,458 per TB case with a
positive treatment outcome (cured or treatment completed).
Sensitivity analysis was performed for different levels of staff
salaries and using discount rates for capital costs of 0% and 3%,
assuming the same effectiveness. Substituting the clinical nurse
practitioner with a staff nurse for all tasks would have reduced the
cost per TB case diagnosed by 9.1% to US$1,015 and the cost per
TB case with positive treatment outcome by 10.9% to US$2,190.
Further reduction in costs would have been achieved if TB
screening had been performed by a lay counsellor and follow-up of
TB cases, supervision, and program management had been
performed by a clinical nurse practitioner. The costs per TB case
diagnosed would have been reduced to US$705 (36.9%) and the
cost per TB case with a positive treatment outcome to US$1,681
(31.6%). Costs per TB case diagnosed increased by 4.9% to
US$1,172 and by 5.1% US$1,174 assuming a discount factor of
0% and 3%, respectively. Changing the discount rate did not
Table 1. Cont.
Variables Total (n = 1,130) HIV2 (n = 534)
Newly Diagnosed
HIV+ (n = 288)
Known HIV
+ (n = 239)
n (%) positive symptom screen 838 (74.2%) 497 (93.1%) 160 (55.6%) 162 (52.6%)
Health seeking behaviour (n = 821)
n (%) sought medical care 170 (20.7%) 112 (23.0%) 19 (11.6%) 39 (23.1%)
n (%) sputum sample sent by the clinic 105 (61.8%) 69 (61.6%) 10 (52.6%) 26 (66.7%)







BMI, body mass index; CXR, chest X-ray.
doi:10.1371/journal.pmed.1001281.t001
Table 2. Tuberculosis prevalence (n = 1,011).
Variables Total (n = 1,011) HIV2 (n = 491)
Newly Diagnosed
HIV+ (n = 243) Known HIV+ (n = 277)
Smear result
n (%) overall positive 20 (2.0%) 11 (2.2%) 8 (3.3%) 1 (0.4%)
n (%) scanty 3 (0.3%) 1 (0.2%) 2 (0.8%) 0 (0.0%)
n (%) 1+ 6 (0.6%) 3 (0.6%) 2 (0.8%) 1 (0.4%)
n (%) 2+ 6 (0.6%) 4 (0.8%) 2 (0.8%) 0 (0.0%)
n (%) 3+ 5 (0.5%) 3 (0.6%) 2 (0.8%) 0 (0.0%)
Culture result
n (%) negative 746 (73.8%) 346 (70.5%) 180 (74.1%) 220 (79.4%)
n (%) contaminated 162 (16.0%) 88 (17.9%) 36 (14.8%) 38 (13.7%)
n (%) MOTT 47 (4.7%) 31 (6.3%) 9 (3.7%) 7 (2.5%)
n (%) M. tuberculosis 56 (5.5%) 26 (5.3%) 18 (7.4%) 12 (4.3%)
Median (IQR) days to culture positivity 13.5 (8–22) 12 (7–17) 13 (8–22) 19 (14.5–27)
MOTT, mycobateria other than TB.
doi:10.1371/journal.pmed.1001281.t002
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substantially affect the cost per TB case with positive treatment
outcome.
Discussion
This study demonstrated that community-based active TB
case finding delivered via a mobile HIV testing service is feasible
and has a high uptake and yield of diagnoses. It highlighted the
losses between TB diagnosis and treatment completion. Out-
comes of the 56 individuals diagnosed with TB were as follows:
34 completed treatment (60.7%), eight (14.3%) initiated
treatment and defaulted or died, eight (14.3%) were contactable
but did not initiate treatment, and six (10.7%) were not
contacted. This study is unique in that it followed patients
beyond the diagnosis of TB and ascertained treatment
outcomes. Once a patient had started TB treatment, treatment
success was more than 80%, which was as high as previously
reported from public service clinics in the Western Cape [18].
Costs were US$1,117 per TB case diagnosed and US$2,458 per
successfully treated TB case.
The service described in this study was accessed by a population
with severe socio-economic deprivation as evidenced by high
unemployment, low income, and low levels of education. Only one
in five individuals with symptoms suggestive of TB had sought
medical attention prior to accessing the service. More importantly
only 13 of the 56 individuals diagnosed with TB had accessed
medical care before attending the mobile clinic. It is well
documented that TB patients and suspects present late to
stationary health facilities, which contributes to delays in diagnosis,
morbidity, and mortality [19].
The prevalence of HIV and severe immunodeficiency in this
mobile HIV testing service were low compared to stationary
services in the Western Cape [10]. This finding and the fact that
only one sputum sample was examined explains the lower yield of
screening in HIV-infected individuals in this study compared to
studies screening individuals at stationary HIV testing sites [9,20]
and at time of ART eligibility screening [21–23]. Furthermore
stationary clinics are likely to be accessed by sicker individuals with
a higher probability of TB disease.
Interestingly, the overall prevalence of TB and the prevalence of
smear-positive disease were lower in known compared to the
newly diagnosed HIV-infected individuals. Median CD4 counts
were comparable in both groups. Individuals known to be HIV
positive regularly engage with the health care system and
development of TB is therefore likely to be detected more rapidly.
Several studies showed a benefit of screening HIV-positive
individuals for TB regardless of symptoms [9]. These studies have
been conducted among severely immune-suppressed individuals
and might not be applicable to mobile services [20–23]. TB
symptom screening regardless of HIV status is likely more
appropriate for mobile settings. Using this strategy in this service
would have decreased the cost per TB case detected by 15% to
US$996, but two TB cases subsequently completing treatment
would have been missed.
Figure 4. Losses between tuberculosis diagnosis to treatment
completion. (1) The reasons for not being able to contact individuals
were: relocation to an unknown area (n = 3), demolition of the area
where the individual had lived (n = 2), and imprisonment (n = 1). (2) Two
individuals had refused treatment and six individuals had not started
treatment at their nearest clinic. Several attempts were made to contact
these individuals, but all of them had moved to an unknown
destination.
doi:10.1371/journal.pmed.1001281.g004
Table 3. Contact rates and treatment success in patients diagnosed with tuberculosis.
Variables Total (n = 56) Smear + (n = 20) Smear 2/Culture + (n = 36)
n (%) successful contact 50 (89.3%) 19 (95.0%) 31 (86.1%)
Median (IQR) time to successful contact
from availability of positive result (d)
4 (1–10) 1 (0–2) 6 (4–20)
Treatment started
n (%) no 2 (4.0%) 1 (5.3%) 1 (3.2%)
n (%) unknown 6 (12.0%) 1 (5.3%) 5 (16.1%)
n (%) confirmed 42 (84.0%) 17 (89.5%) 25 (80.7%)
Median (IQR) time to treatment from screening date (d) 27 (7–54) 6.5 (4.5–8) 45 (32–57)
Median (IQR) time to treatment from
availability of positive result (d)
24 (3–50) 1.5 (0–6.5) 43 (29–74)
Median (IQR) time to treatment from contact date (d) 1 (0–8) 0.5 (0–25) 2 (0–23)
Treatment outcome
n (%) treatment completed or cured 34 (81.0%) 12 (70.6%) 22 (88.0%)
n (%) died 2 (4.8%) 1 (5.9%) 1 (4.0%)
n (%) defaulted 5 (11.9%) 3 (17.6%) 2 (8.0%)
n (%) treatment interruption 1 (2.4%) 1 (5.9) 0 (0.0%)
doi:10.1371/journal.pmed.1001281.t003
Population-Based Active Tuberculosis Case Finding
PLoS Medicine | www.plosmedicine.org 7 August 2012 | Volume 9 | Issue 8 | e1001281
The success of active TB case finding in decreasing transmission
relies on the treatment success of actively found cases. A study
from Nepal reported higher treatment refusal and default rates in
actively compared to passively detected cases [24]. This finding is
of concern as it decreases the effectiveness of active TB case
finding and promotes resistance. However, actively found cases in
Nepal lived further away from the clinic compared to passively
found cases resulting in reduced probability of being diagnosed
passively and completing treatment. The results of our study are
therefore encouraging in showing a treatment success rate of 80%,
which is comparable to outcomes in passively detected cases
reported from clinics in Cape Town [18]. The few other studies
reporting treatment outcomes in actively found cases show similar
results [25–28]. A total of 14 (25%) individuals diagnosed with TB
in this study did not start treatment, which compares favourably to
passively detected cases. Defaulters prior to treatment initiation
are not part of the routine TB outcome reporting, but rates of
initial defaulting of 17%–21% have been reported from stationary
clinics in South Africa using passive case finding [29–32]. More
recently a study conducted in Cape Town reported initial
defaulting rates of patients with smear-negative/culture-positive
TB as high as 39% in the context of passive case finding [33].
Treatment outcomes might be even more important than the
yield of screening. A new rapid diagnostic, the Xpert MTB/RIF
with an overall sensitivity of 90% in TB suspects reduced the time
to start treatment from 56 to 5 d and dropout rates from 39% to
15% in smear-negative/culture-positive cases in a primary health
care clinic in Cape Town [33]. The reduction in diagnostic delay
is particularly important in mobile services. In our study contact
success was higher in individuals with smear-positive disease,
because results were available within 1–2 d, compared to
individuals with smear-negative/culture-positive disease. Relative-
ly more resources and time were spent contacting individuals with
smear-negative/culture-positive disease, as patients’ mobile
phones had stopped working or had been lost, stolen, or passed
on and individuals had moved to different locations in the
meantime. Interventions to decrease losses along the screening
pathway should be aimed at increased uptake and contact success.
Possible interventions to increase uptake include providing
entertainment such as films or incentives to complete screening.
Contact success might be improved by providing incentives for
individuals to return to receive their TB result. A similar approach
has been shown to increase return for HIV results [34]. However,
such interventions would increase the cost of the program and
would have to be balanced against the potential benefit.
This study assessed the cost of community-based active TB case
finding using a mobile screening unit. Three studies investigated
the costs of active TB case finding in HIV-infected individuals only
in stationary clinics in South Africa and Cambodia [23,35,36].
Prevalence of undiagnosed TB in these studies was 19%–26%
[23,36]; in part as a result, the cost per TB case diagnosed in 2011
US$ was more than three times lower (US$318–US$358)
compared to our screening program [23,35,36]. None of these
studies assessed treatment outcomes. The cost per TB case
detected in the mobile screening unit was 4.7 times higher than a
recent estimate for passive case finding in South Africa (US$251)
[17]. However, the passive case-finding estimate assumed a smear
positivity rate of 10%, which is 5 times higher than the one in this
study. The unit cost per suspect screened is therefore roughly
comparable.
It should be borne in mind however that active case finding is
not an alternative to passive case detection (or its enhancement),
but is additional to any existing active case-finding programme
since it targets a different (often harder to reach) suspect
population. A recent modelled cost-effectiveness analysis of passive
case finding using smear microscopy, estimating a cost per case
treated (in 2011 US$) of US$812 for smear only and US$939 for
smear plus culture, found a cost per disability-adjusted life-year
(DALY) averted of US$120 and US$457, respectively [37]. This
estimate of cost per DALY averted are clearly well below a
willingness to pay threshold of one gross domestic product (GDP)
per capita per DALY averted [38] (over US$7280 for South Africa
[39]). In this context, our cost of US$2,458 per case treated,
although 3-fold higher than the cost per case treated under passive
case detection, suggests that further investigation into the cost-
effectiveness of active case finding in South Africa is warranted.
Mobile HIV testing services are widespread in sub-Saharan
Africa and thus these results are likely to inform policy makers
when considering adding active TB case finding to existing mobile
services in a similarly incremental manner. The study was
conducted as part of a routine service and provides an opportunity
to understand the challenges faced by mobile services. Mobile
services operate under time, space, and weather constraints. As a
result a considerable number of individuals were not referred or
did not want to wait for TB screening. Furthermore the population
accessing mobile services are healthier, less health care seeking,
and more mobile than individuals accessing stationary services,
resulting in reduced yield, contact, and treatment initiation rates.
A limitation of the study is that it was conducted at a single
study site; the findings can therefore only be generalised to similar
settings with comparable levels of deprivation and TB prevalence.
In addition generalisability to countries outside of sub-Saharan
Africa with low HIV prevalence is limited. TB prevalence surveys
report similar rates of undiagnosed TB across sub-Saharan Africa
including surveys from Cape Town [40–48]. While this might
suggest a similar yield of active TB case finding in other sub-
Saharan African settings, infrastructure and resources are very
different in South Africa compared to other African countries
affected by the HIV-TB epidemic. Thus liquid culture and sputum
induction might not be viable in these settings. However,
alternative strategies such as collection of spot sputum samples,
use of a mechanical nebuliser [49], investigations limited to smear
microscopy only [6] and Xpert MTB/RIF might be more feasible
in these settings.
South Africa has the second highest absolute number of TB
cases in the world and, together with other countries, including
Swaziland, Lesotho, and Botswana, in the sub-region has the
highest rates of TB globally [50]. Importantly, this epidemic has
completely failed to be controlled by the WHO DOTS strategy
and other more intensive interventions are needed such as active
case finding [51]. As such, these study findings are relevant and
very important to a critical geographic region worst affected by
TB. However, further research of mobile integrated chronic and
infectious disease screening in other sub-Saharan African settings
is needed to address this question.
A recent study from Kenya concluded that the highest impact
would be achieved when population-based active TB case finding
was combined with universal HIV testing and improved diagnosis
of smear-negative TB [52]. Our active TB case-finding program
provided such integrated TB and HIV services combined with
improved TB diagnostics. Our study shows that population-based
integrated disease screening for TB and HIV has a high uptake,
yield, and treatment success at reasonable costs. The study
highlights the challenges faced by mobile population-based
services including high contamination rates, time and weather
constraints, as well as problems contacting individuals with
positive results. New and pragmatic approaches including new
diagnostics such as the Xpert MTB/RIF, information technology,
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incentives, and targeting of high risk groups are needed to improve
efficiency, reduce costs, and expand population-based integrated
screening services.
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Editors’ Summary
Background. In 2010, 8.8 million people developed active
tuberculosis—a contagious bacterial infection—and 1.4
million people died from the disease. Most of these deaths
were in low- and middle-income countries and a quarter
were in HIV-positive individuals—people who are infected
with HIV, the virus that causes AIDS, are particularly
susceptible to tuberculosis because of their weakened
immune system. Tuberculosis is caused by Mycobacterium
tuberculosis, which is spread in airborne droplets when
people with the disease cough or sneeze. Its characteristic
symptoms are a persistent cough, unintentional weight loss,
hemoptysis (coughing up blood from the lungs), fever, and
night sweats. Diagnostic tests for tuberculosis include
sputum smear microscopy (microscopic analysis of mucus
brought up from the lungs by coughing) and culture
(growth) of M. tuberculosis from sputum samples. Tubercu-
losis can be cured by taking several powerful antibiotics daily
for at least 6 months.
Why Was This Study Done? To improve tuberculosis
control, active disease must be diagnosed quickly and
treated immediately. Passive tuberculosis case finding,
which relies on people seeking medical help because they
feel unwell, delays the diagnosis and treatment of
tuberculosis and increases M. tuberculosis transmission.
By contrast, active tuberculosis case finding—where health
workers seek out and diagnose individuals with TB who
have not sought care on their own initiative—has the
potential to reduce tuberculosis transmission by improving
case detection. The World Health Organization (WHO),
which already recommends active tuberculosis case find-
ing in HIV-infected individuals as part of its HIV/TB ‘‘Three
I’s’’ strategy, is currently developing guidelines to inform
the design of national tuberculosis screening strategies
based on the local prevalence of HIV and TB and other
context-specific factors that affect how many individuals
need to be screened to identify each additional new
tuberculosis case (the ‘‘yield’’ of active case finding). Large
gaps in our knowledge about mass-screening strategies
are complicating the development of these guidelines so,
in this observational prospective study, the researchers
assess the feasibility, uptake, yield, treatment outcomes,
and costs of adding an active tuberculosis case-finding
program to an existing mobile HIV testing service in South
Africa.
What Did the Researchers Do and Find? All HIV-
negative adults with symptoms characteristic of tuberculosis
and all HIV-positive adults regardless of symptoms who
attended a mobile HIV testing service operating in deprived
communities in Cape Town, South Africa between May 2009
and February 2011 were eligible for inclusion in the study. Of
the 6,309 adults who accessed the mobile clinic during this
period, 1,385 met these eligibility criteria, and 1,130 were
enrolled and referred for the collection of sputum samples,
which were analyzed by microscopy and culture. The
prevalence of smear-positive tuberculosis was 2.2%, 3.3%,
and 0.4% among HIV-negative study participants, newly
diagnosed HIV-positive participants, and people already
known to have HIV, respectively. The corresponding preva-
lences for smear-negative/culture-positive tuberculosis were
5.3%, 7.4%, and 4.3%, respectively (culture detects more
tuberculosis cases than microscopy but, whereas microscopy
can provide a result within 1–2 days, culture can take several
weeks). Fifty-six new tuberculosis cases were identified, 42
people started tuberculosis treatment, and 34 completed
treatment (a treatment success rate of 81%). Finally, the
incremental cost of the intervention was US$1,117 per
tuberculosis case detected and US$2,458 per tuberculosis
case cured.
What Do These Findings Mean? These findings show
that active case finding for tuberculosis delivered through
a mobile HIV testing service is feasible and has a high
uptake, yield and treatment success in deprived commu-
nities with a high prevalence of HIV and tuberculosis. The
findings also highlight the challenges faced by mobile
population-based services such as losses between tuber-
culosis diagnosis and treatment, which were greatest for
smear-negative/culture-positive people who were more
difficult to contact than smear-positive people because of
the greater time lag between sputum collection and
diagnosis. Because the study was done in a single city,
these findings need to be confirmed in other settings—the
yield of active tuberculosis case finding reported here, for
example, is not likely to be generalizable to countries that
rely on sputum smears for tuberculosis diagnosis. Finally,
given that the incremental cost per case treated in this
study is 3-fold higher than the incremental cost per case
treated under passive case detection in South Africa,
further studies are needed to determine the cost-effective-
ness and affordability of population-based tuberculosis
screening.
Additional Information. Please access these Web sites via
the online version of this summary at http://dx.doi.org/10.
1371/journal.pmed.1001281.
N The World Health Organization provides information on all
aspects of tuberculosis, including information on
tuberculosis and HIV, and on the Three I’s for HIV/TB
(some information is in several languages); details of a
2011 meeting on the development of guidelines on
screening for active tuberculosis are available
N The Stop TB partnership is working towards tuberculosis
elimination; patient stories about tuberculosis/HIV co-
infection are available
N The US Centers for Disease Control and Prevention has
information about tuberculosis, about tuberculosis and
HIV co-infection, and about the diagnosis of tuberculosis
disease
N The US National Institute of Allergy and Infectious Diseases
also has detailed information on all aspects of tuberculosis
N MedlinePlus has links to further information about
tuberculosis (in English and Spanish)
N The Tuberculosis Survival Project, which aims to raise
awareness of tuberculosis and provide support for people
with tuberculosis, provides personal stories about
treatment for tuberculosis; the Tuberculosis Vaccine
Initiative also provides personal stories about dealing
with tuberculosis
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